Organ systems

CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

Retrieved on: 
Tuesday, September 24, 2019
Drugs, Organ systems, Skin care, Anti-inflammatory agents, Pharmacology, Cooking oils, Vegetable oils, Emollients and protectives, Hemp, Shea butter, Cannabidiol, Cannabis

Our seven new body care products continue to deliver on this promise and offer innovative solutions to those seeking alternatives to traditional body care.

Key Points: 
  • Our seven new body care products continue to deliver on this promise and offer innovative solutions to those seeking alternatives to traditional body care.
  • PlusCBD Oil Gold Hemp Balm, Travel Size - Infused with 45mg of concentrated CBD from eco-friendly agricultural hemp, PlusCBD Oil Hemp Balm supports healthy skin in a convenient, travel-size balm.
  • PlusCBD Oil Gold Hemp Body Lotion, Lavender Scent - Infused with 200mg of concentrated CBD from eco-friendly agricultural hemp, hydrating shea butter and nourishing argan oil, PlusCBD Oil Hemp Body Lotion promotes softer skin.
  • PlusCBD Oil Gold Hemp Body Lotion, Grapefruit Scent - Infused with 200mg of concentrated CBD from eco-friendly agricultural hemp, hydrating shea butter and nourishing argan oil, PlusCBD Oil Hemp Body Lotion promotes softer skin.

GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (chronic Autoimmune Disease) to DAS Therapeutics

Retrieved on: 
Tuesday, September 24, 2019
Organ systems, Nervous system, Anatomy, Neurological disorders, Autoimmune diseases, Quaternary ammonium compounds, Neurophysiology, Myasthenia, Weakness, Muscle weakness, Neuromuscular junction, Acetylcholine

GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis.

Key Points: 
  • GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis.
  • Under the terms of the Asset Purchase Agreement, DAS Therapeutics acquires all rights, title, clinical data, composition-of-matter and use patents related to GTB-004.
  • GT Biopharma will receive a $200,000 up-front payment, annual royalties of 1.5% of Net Yearly Sales, and a $6 million payment based on achievement of commercial milestone.
  • Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness.

MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis

Retrieved on: 
Tuesday, September 24, 2019
Research, FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Drugs, Organ systems, Medicine, RTT, Corticosteroids, Betamethasone dipropionate, Glucocorticoids, Calcipotriol/betamethasone dipropionate, Betamethasone, Calcipotriol, Psoriasis, Topical medication, Wynzora™ Cream, MC2 Therapeutics

In a head-to-head Phase 3 clinical trial, Wynzora Cream has demonstrated statistically significant greater efficacy and superior treatment convenience compared to its vehicle and Taclonex Topical Suspension.

Key Points: 
  • In a head-to-head Phase 3 clinical trial, Wynzora Cream has demonstrated statistically significant greater efficacy and superior treatment convenience compared to its vehicle and Taclonex Topical Suspension.
  • With Wynzora Cream we believe that we have responded beyond expectations setting a new standard in daily routines for patients suffering from plaque psoriasis.
  • Wynzora Cream is the first cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis.
  • Wynzora Cream is based on PAD Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in a convenient aqueous formulation.

GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics

Retrieved on: 
Tuesday, September 24, 2019
Organ systems, Nervous system, Anatomy, Neurological disorders, Autoimmune diseases, Quaternary ammonium compounds, Neurophysiology, Myasthenia, Weakness, Muscle weakness, Neuromuscular junction, Acetylcholine

GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis.

Key Points: 
  • GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis.
  • Under the terms of the Asset Purchase Agreement, DAS Therapeutics acquires all rights, title, clinical data, composition-of-matter and use patents related to GTB-004.
  • GT Biopharma will receive a $200,000 up-front payment, annual royalties of 1.5% of Net Yearly Sales, and a $6 million payment based on achievement of commercial milestone.
  • Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness.

Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Chronic Pancreatitis

Retrieved on: 
Tuesday, September 24, 2019
FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Pancreas disorders, Medical specialties, Medicine, Organ systems, Pancreatitis, Pancreas, Chronic pancreatitis, Pancreatic disease, Autoimmune pancreatitis

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases, today announced that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to TLY012 for the treatment of chronic pancreatitis.

Key Points: 
  • Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases, today announced that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to TLY012 for the treatment of chronic pancreatitis.
  • Chronic pancreatitis is a progressive disorder that is characterized by pancreatic inflammation that causes fibrosis, which damages the pancreas and results in the loss of endocrine and exocrine function.
  • Clinical trials evaluating TLY012 for chronic pancreatitis and other fibrotic diseases are expected to begin in 2020.
  • For more information about D&D Pharmatech and Theraly Fibrosis, please visit http://www.ddpharmatech.com/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005251/en/

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Retrieved on: 
Tuesday, September 24, 2019
Organ systems, Endocrine diseases, Diabetes, Endocrine system, RTT, Medical emergencies, Eli Lilly and Company, Hypoglycemia, Blood sugar level, Idiopathic postprandial syndrome, Glucagon, Diabetic hypoglycemia

It is being developed in the ready-to-use HypoPal rescue pen: an auto-injector for easy, fast and effective treatment of severe hypoglycemia in people with diabetes.

Key Points: 
  • It is being developed in the ready-to-use HypoPal rescue pen: an auto-injector for easy, fast and effective treatment of severe hypoglycemia in people with diabetes.
  • The primary result demonstrated that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was superior to placebo (median: 30 min; p
  • Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy.
  • For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

New Analysis From TTS Pharma Reveals More Illegal and Unsafe CBD Products on the UK Market

Retrieved on: 
Tuesday, September 24, 2019
Pharmaceutical, Consumer, Food, Beverage, Cosmetics, Retail, Other Consumer, Biotechnology, Alternative medicine, Health, Drugs, Organ systems, Cannabinoids, Euphoriants, Natural phenols, Appetite stimulants, Entheogens, Cannabidiol, Tetrahydrocannabinol

The analysis shows TTS Pharmas CBD oil is free from THC and CBN as well as harmful environmental contaminants.

Key Points: 
  • The analysis shows TTS Pharmas CBD oil is free from THC and CBN as well as harmful environmental contaminants.
  • A simultaneous landscape analysis of CBD consumer products currently available in the UK revealed a large proportion of products are contaminated with illegal levels of THC and CBN, harmful environmental impurities and inaccurate labelling of CBD content.
  • Alongside the analysis of its own product, TTS Pharma commissioned a landscape study of 31 CBD products currently available on the UK high street.
  • The implications of such a rapidly growing market, being flooded with illegal products, cannot be ignored.

XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies

Retrieved on: 
Friday, September 20, 2019
Medicine, Organ systems, RTT, Medical specialties, Rare diseases, Gangrene, Necrosis, Pyoderma gangrenosum, Pyoderma, Hidradenitis, Atopic dermatitis, Dermatitis

AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases.

Key Points: 
  • AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases.
  • Stanley Kim, Ph.D., J.D., XBiotechs Corporate Vice President of Intellectual Property, stated, I am pleased that the Canadian Patent Office acknowledged the significance of XBiotechs contribution to this field by granting this patent with broad claims.
  • This patent issuance in Canada further broadens XBiotechs patent portfolio as it relates to bermekimab and its potential to treat inflammatory skin disorders through IL-1 alpha blockade.
  • The company has previously successfully completed clinical studies evaluating bermekimab for treatment of atopic dermatitis, psoriasis1, acne2, pyoderma gangrenosum, and hidradenitis suppurativa3.

Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

Retrieved on: 
Friday, September 20, 2019
Branches of biology, Psychoactive drugs, Organ systems, NMDA receptor antagonists, RTT, Neurological disorders, Parkinson's disease, Amantadine, Amines, NMDA receptor, Dyskinesia, L-DOPA

The abrupt and unpredictable transitions between episodes of OFF, dyskinesia and normal movement lead to considerable disruption of patients lives.

Key Points: 
  • The abrupt and unpredictable transitions between episodes of OFF, dyskinesia and normal movement lead to considerable disruption of patients lives.
  • GOCOVRI(amantadine) extended-release capsules is the first and onlyFDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
  • GOCOVRI is thought to work by reducing the amount of glutamate hyperactivity in a region of the brain that controls movement, in patients experiencing dyskinesia and OFF.
  • GOCOVRI, developed by Adamas, is novel in that it selectively blocks the NMDA receptor in a time-dependent manner.

Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Retrieved on: 
Friday, September 20, 2019
Organ systems, Medicine, RTT, Acneiform eruptions, Dermatology, Cutaneous conditions, Hepatotoxins, Papulopustular, Minocycline, Rosacea, Acne, Topical medication

Foamix is a specialty pharmaceutical company working to solve some of todays most difficult therapeutic challenges in dermatology and beyond.

Key Points: 
  • Foamix is a specialty pharmaceutical company working to solve some of todays most difficult therapeutic challenges in dermatology and beyond.
  • With expertise in topical medicine innovation as a springboard, the company is working to develop and commercialize solutions that were long thought impossible, including the worlds first topical minocycline.
  • Its proprietary Molecule Stabilizing Technology (MST) is utilized in the companys dermatology products in late stage development: FMX101 for the potential treatment of moderate-to-severe acne and FMX103 for the potential treatment of moderate-to-severe papulopustular rosacea.
  • Foamix is a different type of specialty pharmaceutical company by design, driven to see the solutions, overcome barriers in all aspects of business, and reimagine whats possible for conditions with high unmet needs.